Waystar Holding Corp is a provider of mission-critical cloud technology to healthcare organizations... Show more
Waystar Holding Corp. holds a commanding position in the healthcare RCM market, providing mission-critical cloud-based software that streamlines payments from patient registration through claims processing. Its platform serves a broad client base, including hospitals, health systems, and ambulatory providers, benefiting from high client satisfaction and sticky adoption due to deep integrations with electronic health records (EHR) systems. The company's scale enables superior payer connectivity and automation capabilities, setting it apart in a fragmented industry. Recent AI-powered tools enhance efficiency in claims management and denial prevention, supporting medium-term market share expansion as healthcare providers prioritize digital transformation. While competitors like R1 RCM challenge in certain segments, Waystar's focus on enterprise-scale solutions and organic growth targets in the low teens through 2031 bolster its outlook.
Waystar's Q2 2026 earnings, anticipated in late July, represent a key near-term event, with investors eyeing updates on revenue growth, adjusted EBITDA margins, and AI platform uptake following Q1's 22% revenue surge to $313.9 million. Quarterly releases will also shed light on client wins and net revenue retention, critical for validating guidance. Product innovations, such as expanded AI-driven RCM features, could drive adoption and feature as catalysts, alongside potential strategic partnerships or M&A to accelerate market penetration. Analyst sentiment remains bullish, with 17-23 firms assigning "Strong Buy" ratings and price targets ranging from $27 to $44, reflecting optimism post-Q1 results; recent maintains from firms like Truist underscore confidence in execution. Regulatory developments in healthcare payments could further influence trajectory.
The healthcare RCM sector benefits from secular tailwinds like rising claims volumes, automation demands, and payer-provider complexities, with AI adoption accelerating efficiency gains. Waystar is well-aligned, as providers seek integrated platforms to combat denials and optimize cash flow. Macro factors exert limited cyclical pressure given healthcare's defensive nature, though elevated interest rates could indirectly slow provider capital spending on tech upgrades. Reimbursement policy changes, inflation in medical costs, and geopolitical stability impacting supply chains for tech infrastructure warrant monitoring. Overall, demographic-driven healthcare spending growth supports Waystar's business model resilience.
Tickeron’s Trend Prediction Engine is an AI-powered forecasting tool that helps traders identify whether a stock, ETF, or other asset may move bullish, bearish, or sideways over the next week or month. It analyzes vast datasets to spot developing trends, evaluate possible breakouts or reversals, and deliver predictions across thousands of tradable instruments. Features include searchable prediction categories, historical performance context, and customizable alerts for timely insights. This neutral, data-driven approach empowers users to make informed decisions—explore it today to enhance your trading strategy.
Waystar's 2026 revenue guidance of $1.274-$1.294 billion positions it for robust expansion, fueled by organic growth, AI enhancements, and client expansion in post-acute and ambulatory care. Long-term drivers include sustained low-teens revenue growth through claims volume increases and RCM automation, alongside margin expansion from scale efficiencies. Key themes encompass technology transitions like deeper AI integration for predictive analytics, competitive threats from new entrants, and regulatory evolution in value-based care. Capital allocation priorities, including debt reduction and share repurchases, could enhance shareholder value. Consensus analyst expectations reinforce a positive trajectory, with price targets implying 40-45% upside, though execution amid industry consolidation remains pivotal.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer. Disclaimers and Limitations
Industry ServicestotheHealthIndustry
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| JEMB | 53.75 | 0.28 | +0.52% |
| Janus Henderson Em Mkts Dbt Hrd Ccy ETF | |||
| IBND | 31.45 | 0.04 | +0.13% |
| State Street® SPDR® Blmbg Intl CorpBdETF | |||
| FEZ | 68.98 | 0.06 | +0.09% |
| State Street® SPDR® EURO STOXX 50® ETF | |||
| NVDB | 29.99 | -0.03 | -0.09% |
| ProShares Ultra NVDA | |||
| BSJV | 26.27 | -0.03 | -0.10% |
| Invesco BulletShares 2031 HY Corp Bd ETF | |||
A.I.dvisor indicates that over the last year, WAY has been loosely correlated with VEEV. These tickers have moved in lockstep 43% of the time. This A.I.-generated data suggests there is some statistical probability that if WAY jumps, then VEEV could also see price increases.
| Ticker / NAME | Correlation To WAY | 1D Price Change % | ||
|---|---|---|---|---|
| WAY | 100% | +1.63% | ||
| VEEV - WAY | 43% Loosely correlated | -1.24% | ||
| HQY - WAY | 39% Loosely correlated | -0.70% | ||
| PHR - WAY | 38% Loosely correlated | +0.11% | ||
| TDOC - WAY | 32% Poorly correlated | +0.41% | ||
| HSTM - WAY | 30% Poorly correlated | -0.34% | ||
More | ||||
| Ticker / NAME | Correlation To WAY | 1D Price Change % |
|---|---|---|
| WAY | 100% | +1.63% |
| Services to the Health Industry industry (46 stocks) | 36% Loosely correlated | -0.98% |
| Health Services industry (247 stocks) | 10% Poorly correlated | -0.71% |
WAY broke above its upper Bollinger Band on June 01, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options. The A.I.dvisor looked at 17 similar instances where the stock broke above the upper band. In of the 17 cases the stock fell afterwards. This puts the odds of success at .
The Momentum Indicator moved below the 0 level on June 08, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on WAY as a result. In of 37 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where WAY declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
The Aroon Indicator for WAY entered a downward trend on May 27, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where WAY's RSI Oscillator exited the oversold zone, of 6 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 3 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
The Moving Average Convergence Divergence (MACD) for WAY just turned positive on May 22, 2026. Looking at past instances where WAY's MACD turned positive, the stock continued to rise in of 18 cases over the following month. The odds of a continued upward trend are .
Following a +1 3-day Advance, the price is estimated to grow further. Considering data from situations where WAY advanced for three days, in of 115 cases, the price rose further within the following month. The odds of a continued upward trend are .
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.913) is normal, around the industry mean (7.394). P/E Ratio (27.985) is within average values for comparable stocks, (50.081). WAY's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (1.188). Dividend Yield (0.000) settles around the average of (0.045) among similar stocks. P/S Ratio (3.053) is also within normal values, averaging (5.606).
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. WAY’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. WAY’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 99, placing this stock worse than average.